StartupsNov 10, 2026, 4:36 PM UTC·2 min read

Efferon raises €4.3M to take sepsis blood-cleansing tech abroad

Biotech firm Efferon has secured €4.3 million from existing DACH investors to expand its sepsis hemoadsorption devices in Europe, India and Latin America.

Intensive care medical staff at a patient's bedside with a blood purification device used in sepsis treatment. — Image: Tech.eu

Efferon, a biotech company developing hemoadsorption devices that remove endotoxins and excessive inflammatory mediators from the bloodstream, has raised €4.3 million from existing private investors in the DACH region.

The technology was originally developed for critical care, including sepsis and septic shock, and is approved and used across Europe. According to the company, more than 30,000 treatments have been performed with its devices, which are distributed in 46 countries through a network of 21 distributors.

Where the money goes

The funding will support the commercial rollout of Efferon's portfolio, including Efferon LPS and Efferon NEO, in Europe, India and Latin America. It will also be used to grow the distributor network, continue regulatory work and strengthen the clinical evidence base.

Efferon reports revenue above €1.1 million in 2025 and expects intensive care products to bring in roughly €5 million in 2027. Subject to successful registration, outpatient products could add up to €3 million more.

"The new investment will support R&D, including the development of new devices and research into applications of the technology in adjacent medical fields," said Co-Founder and CEO Dima Romashin. He added that the results should lay the foundation for a full Series A round and further progress along the regulatory pathway in the United States.

Why India matters

In India, Efferon plans to pair commercial distribution with systematic collection of real-world data: how the technology fits into clinical workflows, how medical teams are trained, and which factors help or hinder adoption. The findings are meant to shape a model for bringing hemoadsorption to new healthcare markets.

By targeting systemic inflammation, which drives critical conditions, chronic diseases and aging-related decline, the company is also looking beyond intensive care towards broader healthcare and healthy aging uses. Its stated goal is to make hemoadsorption more accessible to hospitals and patients, supporting clinicians' efforts to reduce sepsis mortality alongside timely diagnosis and standard intensive care.

Apps worth a look

SUMO: the number puzzle

Tap the right tiles, add them up, hit the target. Easy to learn, hard to master. Free, for all ages.

Dialo: learn languages by speaking

Talk to an AI conversation partner; every sentence comes back corrected and explained in your language. 9 languages, A1 to C2.

ediviewer: read EDI files like documents

Open EDIFACT and X12 messages, see every segment explained, convert to JSON/XML, export PDF and Excel. Runs locally, no upload.

giftdetect: the right gift in minutes

Pick who it is for, the occasion and their personality. The search engine reads product descriptions from local shops and ranks what fits. Free, no sign-up.

Tags:efferonsepsishemoadsorptionfundingbiotechmedtech